Company patents
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. demonstrates a strong and consistent focus on core pharmaceutical innovation, with Heterocyclic Compounds comprising 87.4% of its patent portfolio. While patenting in Pharmaceutical Preparations saw a significant 70.0% YoY growth in 2024, the company appears to be shifting its priorities, with a notable decline in patenting across most categories in 2025 and so far in 2026, including a 100.0% YoY decline in Acyclic / Carbocyclic Compounds and General Organic Chemistry Methods for 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
95 US filings (since 2023) · 6 categories · 5 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Patents
Showing 1-10 of 155